Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25549439 | 0.88 | MT-CO2 (0.43) | CYP19A1CYP11B1CYP11B2TBXA2RTBXAS1 | |
| SCHEMBL25549442 | 0.88 | TBXA2R (0.48) | CYP19A1CYP11B1CYP11B2TBXA2RTBXAS1 | |
| SCHEMBL25549540 | 0.85 | HMOX1 (0.42) | CYP19A1CYP11B1CYP11B2TBXA2RTBXAS1 | |
| SCHEMBL25549438 | 0.81 | MT-CO2 (0.43) | CYP19A1TBXA2RTBXAS1CYP3A4PGR | |
| SCHEMBL25549486 | 0.80 | MT-CO2 (0.47) | CYP19A1CYP11B1CYP11B2TBXA2RTBXAS1 | |
| SCHEMBL25549436 | 0.79 | MT-CO2 (0.43) | CYP19A1TBXA2RTBXAS1CYP3A4PGR | |
| SCHEMBL25549433 | 0.78 | MT-CO2 (0.47) | CYP19A1TBXA2RTBXAS1CYP3A4PGR | |
| SCHEMBL25549441 | 0.78 | MT-CO2 (0.43) | CYP19A1CYP11B1CYP11B2TBXA2RTBXAS1 | |
| SCHEMBL25549432 | 0.77 | MT-CO2 (0.44) | CYP19A1TBXA2RTBXAS1CYP3A4PGR | |
| SCHEMBL15296485 | 0.77 | CYP19A1 (0.41) | CYP19A1CYP11B1CYP11B2TBXA2RTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680062-B2 | 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease | NORTHWEST A & F UNIVERSITY (CN) | 2023-06-20 | — | — | US | disclosed |
| US-20230159503-A1 | 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NORTHWEST A & F UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159503-A1 | 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NOS3, CYP51A1, NOS1 | CYP19A1 71/4885CYP11B1 34/4885CYP11B2 33/4885 |
| US-11680062-B2 | 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease | NOS3, CYP51A1, NOS1 | CYP19A1 71/4885CYP11B1 34/4885CYP11B2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.